8-K: Seelos Therapeutics Amends Convertible Note Agreement, Secures Cash Covenant Relief
Material Definitive Agreement
Seelos Therapeutics has amended its convertible promissory note with Lind Global Asset Management, providing relief from minimum cash balance requirements until October 31, 2024, and extending the deadline for stockholder approval related to the note.
Summary
- Seelos Therapeutics amended its convertible promissory note with Lind Global Asset Management V, LLC on July 16, 2024.
- The amendment provides Seelos relief from maintaining a minimum cash balance until October 31, 2024.
- After October 31, 2024, Seelos must maintain a minimum cash balance equal to 50% of the outstanding principal amount of the note.
- Lind Global Asset Management will not claim a Material Adverse Effect based on events before July 16, 2024, through October 31, 2024.
- The deadline for seeking stockholder approval for issuing shares related to the note has been extended from July 31, 2024, to October 31, 2024.
Sentiment
Score: 6
Explanation: The amendment provides short-term relief but also introduces future financial constraints and the need for stockholder approval. The sentiment is neutral to slightly positive as it addresses an immediate issue but does not resolve the underlying financial challenges.
Positives
- The amendment provides Seelos with immediate relief from the minimum cash balance requirement, improving its short-term financial flexibility.
- The forbearance from asserting a Material Adverse Effect claim provides stability and reduces the risk of immediate conversion of the note.
- The extension of the stockholder meeting deadline allows more time to prepare for the required approvals.
Negatives
- Seelos will be required to maintain a minimum cash balance of 50% of the outstanding principal amount of the note after October 31, 2024, which could constrain future cash usage.
- The company still needs to obtain stockholder approval for issuing shares related to the note, which introduces uncertainty.
Risks
- Failure to maintain the required minimum cash balance after October 31, 2024, could trigger a default under the note.
- The company may face challenges in obtaining stockholder approval for the issuance of shares.
- The note holder retains the right to assert an Event of Default for any events occurring after July 16, 2024.
Future Outlook
The company must seek stockholder approval by October 31, 2024, for issuing shares related to the note and maintain a minimum cash balance after that date. The company's financial flexibility will be impacted by the minimum cash balance requirement.
Management Comments
- The company has agreed to use its reasonable best efforts to seek stockholder approval for the issuance of shares related to the note.
Industry Context
This type of amendment to a convertible note is not uncommon for companies facing short-term liquidity challenges. It provides a temporary reprieve while the company works to improve its financial position. The use of convertible notes is a common financing method for biotech companies.
Comparison to Industry Standards
- Many small-cap biotech companies use convertible notes as a form of financing, especially when traditional equity financing is less attractive.
- The specific terms of the note, such as the minimum cash balance requirement and conversion terms, are typical for this type of financing agreement.
- The forbearance period and extension of the stockholder meeting deadline are common when companies need more time to meet financial obligations or secure necessary approvals.
- Compared to companies like Cassava Sciences or Amylyx Pharmaceuticals, which have also used convertible notes, Seelos's amendment is similar in that it seeks to provide short-term financial flexibility.
Stakeholder Impact
- Shareholders will be impacted by the potential dilution from the issuance of shares related to the note.
- Creditors are impacted by the changes to the terms of the convertible note.
- Employees may be impacted by the company's financial stability and future prospects.
Next Steps
- The company must seek stockholder approval for the issuance of shares related to the note by October 31, 2024.
- The company must maintain a minimum cash balance equal to 50% of the outstanding principal amount of the note after October 31, 2024.
Key Dates
| Date | Description |
|---|---|
| 2021-11-23 | Initial convertible promissory note issued to Lind Global Asset Management V, LLC. |
| 2021-12-10 | First amendment to the convertible promissory note. |
| 2023-02-08 | Second amendment to the convertible promissory note. |
| 2023-05-19 | Third amendment to the convertible promissory note. |
| 2023-09-30 | Fourth amendment to the convertible promissory note. |
| 2024-03-27 | Fifth amendment to the convertible promissory note. |
| 2024-05-01 | Sixth amendment to the convertible promissory note. |
| 2024-06-01 | Seventh amendment to the convertible promissory note. |
| 2024-07-16 | Eighth amendment to the convertible promissory note, effective date of the current filing. |
| 2024-10-31 | Deadline for the company to hold a stockholder meeting and the date the minimum cash balance requirement goes into effect. |
Keywords
convertible note, promissory note, amendment, minimum cash balance, material adverse effect, stockholder approval, Lind Global Asset Management, Seelos Therapeutics, debt financing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.